Intra‐ocular pressure spike after Aflibercept and Ranibizumab intravitreal injections

Purpose Since anti‐VEGFsapproval, intra vitreous injections (IVI) represent a booming therapeutic delivery mode. Immediate ocular hypertension (OHT) induced is known after these IVIs. The purpose of this study is to compare the OHT after Aflibercept and Ranibizumab IVI. Methods In this prospective study, we compared 30 patients who received an Aflibercept IVI (0.05 mL) to 30 patients who received Ranibizumab for wet AMD. IVI were performed with a 30G needle pushed to the hilt with an anti‐reflux system. We measured intraocular pressure (IOP) using a portable aplanation tonometer PERKINS MK2 (Haag‐Streit, Koeniz, Switzerland) before injection (T0), immediately after IVI (T1), 5 minutes (T5), 15 minutes (T15) and 45 minutes (T45) after the IVI. IOP were compared by a t‐test. Results In Aflibercept group, at T0, IOP was 13.4 mmHg+1.5. All patients had a significant increase in IOP at T1 (42.7 mmHg+3, p